Takeda gives Affymax $10M milestone payment for anemia therapy

08/10/2011 | Forbes

Takeda Pharmaceutical paid a $10 million milestone fee to Affymax after the FDA accepted a marketing application for anemia drug candidate peginesatide. The companies aim to co-promote the drug to anemic patients with chronic renal failure.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN